Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma

International Journal of Medical Sciences

Volumn 10, Issue 10, 2013, Pages 1375-1386

  Yan, Sen Xiang ^a   Luo, Xing Mei ^a   Zhou, Shui Hong ^a   Bao, Yang Yang ^a   Fan, Jun ^a   Lu, Zhong Jie ^a   Liao, Xin Biao ^a   Huang, Ya Ping ^a   Wu, Ting Ting ^a   Wang, Qin Ying ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antisense oligodeoxynucleotides; Glucose transporter 1; Laryngeal carcinoma; Radio sensitivity

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GLUCOSE TRANSPORTER 1; MESSENGER RNA; COMPLEMENTARY DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARYNX CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SURVIVAL RATE; ANIMAL; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; LARYNGEAL NEOPLASMS; PHYSIOLOGY; RADIATION RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, ANTISENSE; FLOW CYTOMETRY; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LARYNGEAL NEOPLASMS; MICE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84883008753     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6855     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008; 9:288-96.
3. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol. 2012; 23: 352-61.
4. Han MW, Lee HJ, Cho KJ, et al. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck. 2012;34:1395-402
5. Alakus H, Batur M, Schmidt M, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010;31:532-8.
6. Nagamatsu A, Umesaki N, Li L, Tanaka T. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010;23:1069-76.
7. Li XF, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med. 2010;51:632-8.
8. Li LF, Zhou SH, Zhao K, et al. Clinical significance of FDG single-Photon emission computed tomography: computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm. 2008; 23: 701-4.
9. Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 2010;38:1885-92.
10. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 2011; 11:167.
11. Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec. 2008;70:189-94.
12. Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH. Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett. 2012; 5: 261-6.
13. Kunkel M, Moergel M, Stockinger M, et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007,43:796-803.
14. Doki Y, Takachi K, Ishikawa O, et al. Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy. Surgery. 2005; 137:536-44.
15. Markowska J, Grabowski JP, Tomaszewska K, et al. Significance of hypoxia in uterine cervical cancer. Multicentre study. Eur J Gynaecol Oncol. 2007; 28:386-8.
16. Zhou SH, Fan J, Chen XM, Cheng KJ, Wang SQ. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisensecoligonucleotides against glucose transporter-1. Head Neck. 2009; 31:1624-33
17. Xu YY, Bao YY, Zhou SH, Fan J. Effect on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2 cell line by antisense glucose transporter-1. Arch Med Res. 2012; 43:395-401.
18. Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res. 2012;18:721-8.
19. Pez F, Dayan F, Durivault J, et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011;71: 1647-57.
20. Yasuda M, Miyazawa M, Fujita M, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep. 2008; 19:111-6.
21. Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008; 61: 377-93.
22. Ke CC, Liu RS, Yang AH, et al. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging. 2013;40:61-71.
23. Mai HM, Zheng JW, Wang YA, et al. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chin Med J (Engl). 2013; 126: 88-94.
24. Xie G, Zhan J, Tian Y,et al. Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance. Cancer Lett. 2012;316:53-61.
25. Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011;313:64-75.
26. Hematulin A, Meethang S, Ingkaninan K, Sagan D. Derris scandens Benth extract potentiates radioresistance of Hep-2 laryngeal cancer cells. Asian Pac J Cancer Prev. 2012;13:1289-95.
27. Chen CP, Li XX, Zhang LR, et al. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 Cells. Bioconjug Chem. 2002;13:525-9.
28. Choi JW, Yoon DJ, Lee HW, Han DP, Ahn YH. Antisense GLUT1 RNA suppresses thetransforming phenotypes of NIH 3T3 cells transformed by N-Ras. Yonsei Med J. 1995; 36: 480-6.
29. Chan JY, Kong SK, Choy YM, Lee CY, Fung KP. Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci. 1999; 65: 63-70.
30. Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2000; 154: 175-82.
31. Ito S, Nemoto T, Satoh S, Sekihara H, Seyama Y, Kubota S. Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophy.s 2000; 373: 72-82.
32. Liu TQ, Fan J, Zhou L, Zheng SS. Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int. 2011; 10: 72-7.